From its establishment in 2005, J-Pharma, a clinical stage bio-venture company with a special focus on membrane transporters, has been conducting an array of unique drug developments by Hitoshi Endou, MD., Ph.D., formerly a professor of Kyorin University Faculty of Medicine. Recently J-Pharma has been placing the highest priority on the clinical development of its original inhibitors of L-type amino acid transporter 1 (“LAT1”) for the treatment of advanced cancer patients who failed to benefit from standard chemotherapy.
JPH203, a small molecule that targets biliary tract cancer, is currently in Phase IIb trials with results expected in 2Q 2022. In the U.S., we are targeting breakthrough designation in 1Q 2023 and FDA approval in 4Q 2026. Another small molecule LAT-1 inhibitor, OKY034, is being developed for autoimmune disease with a US IND expected in 4Q 2022.